Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis.

The high prevalence of hypermutable (mismatch repair-deficient) Pseudomonas aeruginosa strains in patients with cystic fibrosis (CF) is thought to be driven by their co-selection with adaptive mutations required for long-term persistence. Whether the increased mutation rate of naturally hypermutable strains is associated with a biological benefit or cost for the colonization of secondary environments is not known. Thirty-nine P. aeruginosa strains were collected from ten patients with CF during their course of chronic lung infections and screened for hypermutability. Seven hypermutable P. aeruginosa strains (18 %) isolated from six patients with CF (60 %) were identified and assigned to five different genotypes. Complementation and sequence analysis in the mutS, mutL and uvrD genes of these hypermutable P. aeruginosa strains revealed novel mutations. To understand the consequences of hypermutation for the fitness of the organisms, five pairs of clinical wild-type/hypermutable, clonally related P. aeruginosa strains and the laboratory strains PAO1/PAO1DeltamutS were subjected to competition in vitro and in the agar-beads mouse model of chronic airway infection. When tested in competition assay in vitro, the wild-type outcompeted four clinical hypermutable strains and the PAO1DeltamutS strain. In vivo, all of the hypermutable strains were less efficient at establishing lung infection than their wild-type clones. These results suggest that P. aeruginosa hypermutation is associated with a biological cost, reducing the potential for colonization of new environments and therefore strain transmissibility.

[1]  J. A. Bass,et al.  A rat model of chronic respiratory infection with Pseudomonas aeruginosa. , 2015, The American review of respiratory disease.

[2]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[3]  J. Klockgether,et al.  Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. , 2006, Microbiology.

[4]  Li Li,et al.  Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial , 2006, Genome Biology.

[5]  J. Heesemann,et al.  Sequence variability and functional analysis of MutS of hypermutable Pseudomonas aeruginosa cystic fibrosis isolates. , 2006, International journal of medical microbiology : IJMM.

[6]  M. Maciá,et al.  Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[7]  A. Oliver,et al.  Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections , 2005, Antimicrobial Agents and Chemotherapy.

[8]  G. Pier,et al.  Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. , 2005, The Journal of infectious diseases.

[9]  N. Høiby,et al.  Occurrence of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation , 2005, Antimicrobial Agents and Chemotherapy.

[10]  B. Levin,et al.  Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections , 2004, Antimicrobial Agents and Chemotherapy.

[11]  O. Berg,et al.  Experimental Adaptation of Salmonella typhimurium to Mice , 2004, Genetics.

[12]  Michael E. Watson,et al.  Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. , 2004, Microbiology.

[13]  A. Oliver,et al.  Lack of Association between Hypermutation and Antibiotic Resistance Development in Pseudomonas aeruginosa Isolates from Intensive Care Unit Patients , 2004, Antimicrobial Agents and Chemotherapy.

[14]  J. Campos,et al.  Dynamics of Long-Term Colonization of Respiratory Tract by Haemophilus influenzae in Cystic Fibrosis Patients Shows a Marked Increase in Hypermutable Strains , 2004, Journal of Clinical Microbiology.

[15]  T. Pitt,et al.  European-wide distribution of Pseudomonas aeruginosa clone C. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  I. Kukavica-Ibrulj,et al.  In vivo functional genomics of Pseudomonas aeruginosa for high-throughput screening of new virulence factors and antibacterial targets. , 2003, Environmental microbiology.

[17]  R. Leclercq,et al.  High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. , 2003, The Journal of infectious diseases.

[18]  A. Camilli,et al.  Large‐scale identification of serotype 4 Streptococcus pneumoniae virulence factors , 2002, Molecular microbiology.

[19]  M. Elkins,et al.  Genetic Analysis of Pseudomonas aeruginosa Isolates from the Sputa of Australian Adult Cystic Fibrosis Patients , 2002, Journal of Clinical Microbiology.

[20]  A. Charbit,et al.  A hypermutator phenotype attenuates the virulence of Listeria monocytogenes in a mouse model , 2002, Molecular microbiology.

[21]  A. Oliver,et al.  The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants , 2002, Molecular microbiology.

[22]  Richard C Boucher,et al.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. , 2002, The Journal of clinical investigation.

[23]  F. Taddei,et al.  Costs and Benefits of High Mutation Rates: Adaptive Evolution of Bacteria in the Mouse Gut , 2001, Science.

[24]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[25]  S. Campoy,et al.  Virulence and mutation rates of Salmonella typhimurium strains with increased mutagenic strength in a mouse model. , 2000, FEMS microbiology letters.

[26]  A. Oliver,et al.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. , 2000, Science.

[27]  F. Taddei,et al.  Evolution-driving genes. , 2000, Research in microbiology.

[28]  J. Miller,et al.  The consequences of growth of a mutator strain of Escherichia coli as measured by loss of function among multiple gene targets and loss of fitness. , 2000, Genetics.

[29]  S. Maloy,et al.  Effect of mutS and recDMutations on Salmonella Virulence , 1999, Infection and Immunity.

[30]  B. Tümmler,et al.  Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  B. Tümmler,et al.  Large genome rearrangements discovered by the detailed analysis of 21 Pseudomonas aeruginosa clone C isolates found in environment and disease habitats. , 1997, Journal of molecular biology.

[32]  R. Lenski,et al.  Evolution of high mutation rates in experimental populations of E. coli , 1997, Nature.

[33]  F. Taddei,et al.  Role of mutator alleles in adaptive evolution , 1997, Nature.

[34]  W. L. Payne,et al.  High Mutation Frequencies Among Escherichia coli and Salmonella Pathogens , 1996, Science.

[35]  T. Pitt,et al.  The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. , 1996, Journal of medical microbiology.

[36]  V. Deretic,et al.  Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. , 1995, Trends in microbiology.

[37]  B. Tümmler,et al.  Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients , 1991, Journal of clinical microbiology.

[38]  M. Thomassen,et al.  Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition , 1985, Infection and immunity.

[39]  L. Chao,et al.  COMPETITION BETWEEN HIGH AND LOW MUTATING STRAINS OF ESCHERICHIA COLI , 1983, Evolution; international journal of organic evolution.

[40]  E. Friedberg,et al.  DNA Repair and Mutagenesis , 2006 .

[41]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[42]  J. Miller,et al.  Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. , 1996, Annual review of microbiology.